Spruce Biosciences Reports $28.5 Million Net Loss in First Half of 2026

Spruce Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $28.5 million for the first half of 2026, compared to a loss of $16.1 million during the same period in 2025, reflecting an increase in operating expenses primarily driven by heightened research and development activities. Total operating expenses surged to $28.5 million in the first half of 2026, up from $17.2 million in the prior year, with research and development costs alone rising to $19.7 million from $10.4 million. The company’s accumulated deficit reached $317.7 million as of June 30, 2026, indicating ongoing financial challenges as it continues to invest heavily in its product pipeline.

In terms of liquidity, Spruce Biosciences reported cash and cash equivalents of $96.3 million as of June 30, 2026, a substantial increase from $48.9 million at the end of 2025. This increase was bolstered by a successful public offering in April 2026, which generated net proceeds of $64.4 million, and a private placement in August 2026 that raised an additional $5.5 million. The company anticipates that its current cash reserves, along with the proceeds from the recent financing activities, will be sufficient to fund operations and meet debt obligations for at least the next 12 months.

Strategically, Spruce is focused on advancing its lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), which is being developed for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB). The company has received several designations from the U.S. Food and Drug Administration (FDA), including Breakthrough Therapy Designation, and plans to submit a biologics license application in the fourth quarter of 2026. The company is also preparing for a confirmatory study and an expanded access program for TA-ERT, which are expected to begin in late 2026.

Operationally, Spruce has faced challenges, including increased costs associated with clinical development and manufacturing for TA-ERT. The company reported a significant rise in clinical development expenses, which were primarily related to TA-ERT, reflecting its commitment to advancing this therapy through the regulatory process. Additionally, the company has been actively managing its workforce and resources to support its clinical and operational needs, although it currently lacks a marketing and sales organization, which could impact future revenue generation.

Looking ahead, Spruce Biosciences acknowledges the need for substantial additional financing to support its ongoing development programs. The company faces various risks, including the potential for delays in clinical trials, regulatory approvals, and the competitive landscape in the biotechnology sector. As it continues to navigate these challenges, Spruce remains focused on its strategic objectives and the successful commercialization of TA-ERT, while also monitoring macroeconomic conditions that could affect its operations and financial performance.